Indeed, systemic treatment with Flt3L, leading to supraphysiological Flt3L levels, resulted in the expansion of cDCs and pDCs in the TME of mouse melanoma and reduced tumor growth when used in combination therapies (5, 6). This evidence concerns the gene FLT3LG and melanoma.